Aggregator

慢性腎臓病と高血圧がある人にとって、血圧目標値を標準的な降圧目標値より低く設定すると、より多くの利益が得られるか?

1 year ago
慢性腎臓病と高血圧がある人にとって、血圧目標値を標準的な降圧目標値より低く設定すると、より多くの利益が得られるか? 主要な結果 ・血圧が高い人(高血圧患者)の血圧を下げると、健康上の利益が得られる。しかし、高血圧と慢性腎臓病の両方がある人において、血圧目標値をどれだけ低くするべきかはわかっていない。 ・血圧目標値を標準的な降圧目標値より強化しても(標準的な降圧目標値より血圧を下げても)、慢性腎臓病がある人の死亡数、重篤な好ましくない有害事象、あるいは心血管系イベント(心臓や血管に影響を与える疾患)は減らない可能性がある。血圧目標値を低くしても、心血管系疾患に関わる死亡数を減らしたり、腎臓病の悪化を遅らせたりすることはできないかもしれない。 慢性腎臓病とは? 慢性腎臓病とは、腎臓の機能が低下および損傷し、血液を正常に濾過できなくなる長期的な疾患である。慢性腎臓病は時の経過と共に進行しうるため、いずれは腎臓がまったく機能しなくなる可能性がある。高血圧(異常に高い血圧)は糖尿病に次いで二番目に多くみられる慢性腎臓病の原因である。 慢性腎臓病はどのように治療するか? 高血圧と慢性腎臓病がある人に対する治療法はないが、血圧を下げることで腎臓病の進行を遅らせることができる。しかし、最適な血圧水準についてはまだよくわかっていない。 知りたかったこと 知りたかったことは、高血圧と慢性腎臓病がある...

SARS-CoV-2感染者を診断するのに、(RNA抽出・精製を事前に行ったRT-PCR検査に代わる)検査室で行う分子検査はどの程度正確なのか?

1 year ago
SARS-CoV-2感染者を診断するのに、(RNA抽出・精製を事前に行ったRT-PCR検査に代わる)検査室で行う分子検査はどの程度正確なのか? 要点 * TMA検査(逆転写酵素とRNA合成酵素を利用した、核酸増幅検査)と、RNA(ほとんどの生物学的機能に必須な分子)を抽出・精製する工程を省けるように特別に設計された市販のRT-PCR検査(逆転写ポリメラーゼ連鎖反応を利用した、核酸増幅検査)は、新型コロナウイルス(SARS-CoV-2)感染者を特定するために、RNAの抽出・精製を事前に行うRT-PCR検査に取って代わるのに十分な精度があると思われる。しかし、エビデンスには若干の限界があるため、これらの結果は慎重に解釈・使用する必要がある。 * 他の検査室で行う分子検査の精度は、RT-PCR検査の代替検査として行うには、世界保健機関(WHO)が推奨する基準を下回っているか、信頼できる結論を導き出すのに十分な量のエビデンスがない。 * 評価した検査から得られた精度に関するデータを同じ技術を用いた他ブランドの検査に外挿することは、解析した主な検査手法がそれぞれ高精度だったブランドの検査によって占められていたため、困難である。実際の臨床現場におけるこれらの検査については、さらなる評価が必要である。 SARS-CoV-2感染者を特定するための、検査室で行う分子検査にはどのようなものがあるか?...

Cochrane announces new scientific strategy

1 year ago

The Cochrane Collaboration is proud to announce our new scientific strategy, focusing on tackling the most pressing global health issues driving inequity. 

Over the past 30 years, we have published over 9,000 systematic reviews and developed a reputation as one of the most trusted sources of health evidence. Our reviews set standards and improve lives, from offering premature babies the best start in life to preventing falls among older people. We now want to go further to address the devastating health inequalities that still persist worldwide. 

The new scientific strategy will contribute to the United Nations Sustainable Development Goals (SDGs), which aim to bring about a more sustainable, equitable, and prosperous future by 2030. We will collaborate with partners both within and beyond the Cochrane community to tackle inequity across the world, building a healthier future for everyone and helping to achieve the SDGs.

Our strategy focuses on four key research priorities to address the most pressing health challenges, underpinned by a foundation of four commitments. Our research priorities are:

  • Maternal, newborn and child health: we will improve the health and wellbeing of mothers and children worldwide and tackle the vast health equity gap between different populations. 

  • Multiple chronic conditions: we will improve the lives of people living with multiple chronic conditions, identifying effective approaches to provide person-centred care and prevent further illness. 

  • Infectious diseases: we will equip people across the world with the evidence they need to protect themselves against both existing and emerging threats. 

  • Climate change and sustainability: We will improve our understanding of the complex relationships between climate change and human health, helping people to better cope with the health impacts of climate change. 

Our commitments are: 

  • Innovate in methods: we will build on our world-leading expertise developing innovative research methods, including harnessing the power of artificial intelligence (AI). 

  • Promote health equity: we will be guided in everything we do by our desire to promote health equity, shaping the questions we address and how we share our findings. 

  • Collaborate and involve: we will collaborate with global partners, national agencies and local healthcare consumers to drive transformative change. 

  • Champion research integrity: we will maintain and strengthen our leadership in research integrity so that we continue to produce evidence that everyone can trust. 

“In an era marked by unprecedented global health challenges, the need for reliable, high-quality health evidence has never been more critical,” writes Dr Karla Soares-Weiser, Cochrane’s Editor in Chief. “From the rise of infectious diseases such as polio and malaria due to war and poverty to the profound health impacts of climate change, our world faces a myriad of crises that demand informed, evidence-based responses. Yet, despite significant advancements in health research, a gap remains in making trusted health evidence accessible and useable for those on the frontlines — especially in low- and middle-income countries with limited resources. 

“Global health inequalities continue to mean that millions suffer and die from preventable health risks daily. Without dependable evidence, healthcare professionals, patients, and policy makers struggle to make informed decisions that could alleviate these hardships and save lives. At Cochrane, we understand this urgency and the indispensable role of robust evidence in bridging health disparities across the globe. 

“Our scientific strategy for 2025-2030 is a bold response to this challenge. By streamlining our processes and focusing on the most pressing global health issues, we aim to bridge the current evidence gap. Our priorities reflect today’s realities, centring on maternal, newborn, and child health; multiple chronic conditions; infectious diseases and pandemics; and the health effects of climate change. These focus areas are not only a response to the current health landscape but also a proactive approach to shaping a future where health decisions are consistently informed by the best possible evidence. 

“Cochrane has dedicated over three decades to improving global health and life expectancy through trusted evidence. We have systematically reviewed and analysed health research, using innovative statistical methods to ensure findings that are both robust and reliable. We are now keen to collaborate with partners and attract funders to join us on this vital mission. Together, we can harness the power of evidence to overcome today’s most urgent health challenges and build a healthier, more equitable world for all.” 

Thursday, October 24, 2024 Category: The difference we make
Muriah Umoquit

Cochrane seeks Editorial Assistant - Flexible (remote)

1 year ago

Title: Editorial Assistant 
Specifications: Full Time Permanent Contract
Salary: £26,000 per annum
Location: Flexible (remote)
Application Closing Date: 22 October 2024 (midnight GMT)

Cochrane has established a Central Editorial Service to support the efficient and timely publication of high-quality systematic reviews in the Cochrane Library. The reviews that are published through the Central Editorial Service address some of the research questions considered to be the most important to decision makers. 

The Editorial Assistant will perform editorial tasks to support the smooth running of the Editorial Service. Tasks will include, but are not limited to: performing checks on manuscripts on submission and before publication; supporting the peer-review process including inviting peer reviewers and tracking progress; assisting authors and peer reviewers to use Cochrane’s Editorial Management System; running editorial reports for the Editorial Service Executive Editor; arranging and preparing documents for editorial meetings; and supporting the Head of Editorial in projects aimed at improving or developing editorial systems and processes.

Cochrane is a global independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making the vast amounts of evidence generated through research useful for informing decisions about health. We do this by identifying, appraising and synthesizing individual research findings to produce the best available evidence on what can work, what might harm and where more research is needed.

How to apply

  • For further information on the role and how to apply, please click here.
  • The deadline to receive your application is 22 October 2024 (midnight GMT).
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Read our Recruitment Privacy Statement

 

 

Thursday, October 10, 2024 Category: Jobs
Mia Parkinson

Cochrane reviews inform WHO Guidelines for preterm infant care 

1 year ago

Cochrane’s systematic reviews are playing a key role in informing the World Health Organization’s (WHO) guidelines for managing preterm infants, including respiratory interventions. These reviews, led by Cochrane Sweden and Cochrane Neonatal, are providing the evidence that is directly shaping recommendations on treatments like caffeine therapy to support lung function in preterm babies. 

Preterm birth remains one of the leading causes of infant mortality worldwide. In response, the WHO regularly updates its guidelines to enhance care and improve outcomes for these vulnerable infants. By basing its recommendations on the latest and most reliable data from Cochrane reviews, the WHO ensures that its guidance remains both relevant and evidence based. 

“Our guideline development process is very rigorous and evidence-based,” says Marge Reinap Technical Officer, Evidence-based Policy at the WHO. “All our questions and recommendations rely on evidence synthesis. Without evidence synthesis, the guideline development panel cannot issue a recommendation. The evidence synthesis developed by Cochrane is instrumental and serves as the pillar point of WHO’s normative guidance, facilitating discussions and forming recommendations.”  

The collaboration began when the WHO commissioned Cochrane Sweden and Cochrane Neonatal to conduct systematic reviews on interventions for preterm infants. These reviews, led by Matteo Bruschettini, Director of Cochrane Sweden, explored the evidence around caffeine to improve health outcomes for preterm infants. Studies have shown that caffeine therapy improves lung function and reduces both mortality and long-term disabilities in preterm infants. 

The impact of these Cochrane reviews on WHO guidelines was immediate. The evidence gathered was directly incorporated into the WHO’s updated recommendations on the care of preterm infants, giving healthcare providers around the world clear, evidence-based guidance to improve the survival and health outcomes of these infants. 

Beyond influencing global policy, Cochrane Sweden is now working on adapting the WHO guidelines for the Swedish healthcare system. This framework, known as ‘GRADE ADOLOPMENT’, involves modifying guidelines made by others to fit specific national contexts. GRADE refers to the ‘Grading of Recommendations, Assessment, Development and Evaluation’ approach, while ‘ADOLOPMENT’ means adopting, adapting, and/or developing new recommendations. 

“Combining the strengths of the Cochrane network, evidence and methodologies with the GRADE ADOLOPMENT framework is very helpful for making recommendations applicable to the Swedish setting,” says Matteo Bruschettini. “It’s an efficient way to make tailored recommendations based on solid foundations, without duplicating efforts.” 

Cochrane Sweden, in collaboration with the WHO and members from the GRADE Working Group are working towards that the adapted guideline are tailored to the Swedish needs and healthcare environment while maintaining the same high standard of evidence-based recommendations. 

While WHO’s guidelines provide a comprehensive framework, countries often need to adjust them to align with their healthcare systems. In Sweden, Cochrane’s work focuses on ensuring that the guidelines not only address local concerns but also meet the practical needs of healthcare providers. This demonstrates how robust global evidence can be translated into actionable, country-specific recommendations. 

“We’re in the process of making guidelines made by others more used in the Swedish setting,” says Martin Ringsten, Project Coordinator at Cochrane Sweden. “It would save a lot of time and resources to use the evidence included in guidelines made by others. Guideline developers can then adopt or adapt recommendations and add contextual evidence where it’s needed.”  

Cochrane Sweden’s involvement in the development and adaptation of these guidelines and included systematic reviews highlights how systematic reviews inform clinical guidelines and public health policy. This collaboration ensures that healthcare recommendations are based on the best available evidence and contextualized to the applicable settings, thereby enhancing the quality and relevance of healthcare practices at both global and national levels. 

The process of using and contextualizing guidelines for specific settings illustrates how Cochrane reviews integrated into these guidelines can directly impact healthcare practice and policy, both globally and nationally. 

 

Wednesday, October 9, 2024 Category: The difference we make
Christine Maema

Cochrane helps launch new WHO guidance on best practices for clinical trials

1 year ago

The World Health Organization (WHO) has recently launched new guidance on best practices for clinical trials. The document aims to reinforce global standards in the organization, design, conduct, analysis and reporting of clinical trials. It responds to calls in World Health Assembly resolution 75.8, which emphasized the urgent need to enhance both global and national clinical trial ecosystems to generate high-quality evidence on health interventions. 

Cochrane’s Editor in Chief, Dr Karla Soares-Weiser, contributed to the technical advisory group established to support the resolution and this guidance. 

The WHO guidance offers practical recommendations to assist national health authorities, regulatory authorities, funders and others in facilitating effective clinical trials and research. Key recommendations centre on improving trial design to ensure the relevance of research; an emphasis on scientific and ethical standards; strengthening of capacity and support for sustainable research infrastructure; enhancing clinical trial transparency; and reforms to enable underrepresented groups to participate in clinical trials. 

Eva Madrid, the Lead of Cochrane’s new Iberoamérica Evidence Synthesis Unit, spoke on the panel of the launch event for the new guidance. She highlighted the need for greater engagement between those conducting clinical trials and the evidence synthesis community. Eva stated: 

“Disregarding existing evidence leads to redundant findings and fails to prioritize the gaps that we need to fill, missing the opportunity to resolve clinical uncertainties with clinical trials." 

In his opening  statement, Dr Jeremy Farrar, WHO Chief Scientist, said: “Clinical trials are the bedrock of clinical and public health policymaking and evidence informed policymaking” and urged that they should not only be set up in times of crisis and are used for “answering critically important and clinical and public health questions all of the time.” 

If you would like to find out more about Cochrane’s work on clinical trials, please get in touch with the Advocacy and Partnerships Team: msalman@cochrane.org

Tuesday, October 8, 2024 Category: The difference we make
Muriah Umoquit

Cochrane Ireland and Cochrane Crowd empower citizen scientists in The People’s Review

1 year ago

Cochrane is excited to announce the The People’s Review, a project designed to empower individuals worldwide to take part in a systematic review. The People’s Review invites the public to learn about systematic reviews by directly participating in the process. The People's Review is brought to you by Evidence Synthesis Ireland and Cochrane Ireland.

The People’s Review will be hosted on the Cochrane Crowd platform, which already supports various citizen science tasks related to systematic reviews. It will help guide participants through eight interactive stages— from choosing the review question to sharing the final results.

What Makes The People’s Review Special?

In an age of overwhelming information and online health advice, it’s crucial to have tools that allow individuals to navigate complex medical data. Systematic reviews offer a structured and reliable way to assess healthcare treatments. By involving the public in conducting one, The People’s Review seeks to demystify the process and equip participants with essential critical thinking skills for health decision-making.


 Éle Quinn, is a PhD student at University of Galway and is working alongside Evidence Synthesis Ireland and Cochrane Ireland on this project. Éle is the lead behind The People’s Review and shares her enthusiasm for the project and its potential impact:

“The power of systematic reviews is extraordinary. Especially in a world where we are bombarded with information 24/7. Finding reliable sources to help make choices, especially health choices is more difficult than ever. The People's Review is an exciting opportunity opening up the world of health research to the wider public in a unique even a fun way!”

The Cochrane Crowd platform hosts tasks that help identify and describe health research for systematic reviews. Many within the Crowd community have fed back that the experience helps build skills around understanding health evidence. Each task is always supported by brief (and fun!) interactive training, and any contribution is welcome. Anna Noel-Storr, Cochrane Crowd Lead adds:

"We’re thrilled to be part of this exciting initiative. Cochrane Crowd has always been about engaging the public in evidence production, and The People’s Review is the next step in empowering individuals to contribute to systematic reviews directly."

April English, Cochrane's Patient and Public Involvement Manager, highlights the importance of this project:

"The People's Review is an inspiring project that empowers the public. I see it as a valuable opportunity to learn from and help build trust in research by making it more inclusive and transparent. I look forward to continuing to collaborate on this important work."

Get Involved and Stay Updated

Everyone, regardless of background or experience, is welcome to join The People’s Review. Whether you have a smartphone, tablet, or computer, you can participate from anywhere in the world. This project is designed to be inclusive and accessible to all.

Be part of this unique opportunity to engage with health research! The project will go through 8 different stages. The first stage is now live, so sign up if you're interested in suggesting a question you want answered. To stay informed about opportunities to get involved, sign up for the newsletter and be the first to know about each new step in The People’s Review.

The People’s Review is funded by the Health Research Board (Ireland) (ESI-2021-001) and the HSC Research and Development Division of the Public Health Agency (Northern Ireland) through Evidence Synthesis Ireland and Cochrane Ireland. Éle Quinn’s PhD studentship was funded by the College of Medicine, Nursing and Health Sciences, University of Galway, Ireland through Evidence Synthesis Ireland.

 

Thursday, April 24, 2025
Muriah Umoquit

水道水へのフッ化物添加はむし歯の予防に有効か?

1 year ago
水道水へのフッ化物添加はむし歯の予防に有効か? 要点 - 水道水へのフッ化物添加は、小児における乳歯のう蝕をわずかに減少させる可能性がある - 水道水へのフッ化物添加は、う蝕に罹患していない小児がわずかに増える可能性がある - 水道水へのフッ化物添加の利点は、歯磨き粉(歯磨剤)へのフッ化物添加が普及する以前よりも少ない可能性がある むし歯(う蝕)とフッ化物の使用 むし歯(う蝕)は、成人や小児のほとんどが罹患する世界的な問題である。う蝕を治療せずに放置すると、痛みを引き起こし、歯を抜かなければならなくなる可能性もある。 フッ化物は無機物として水中にさまざまな濃度で存在し、う蝕を予防する効果がある。1975年以降、フッ化物はほとんどの歯磨剤に含まれている。フッ化物は洗口液にも使用されており、歯科医師はフッ化物を治療に応用している。また、地域の水道水にフッ化物を添加することも可能であり、この場合、当該地域のすべての人に対しフッ化物を応用することができる。 小児が永久歯の形成期にフッ化物を過剰に摂取すると、永久歯に白い斑点が生じることがあり、これは歯のフッ素症と呼ばれる。歯のフッ素症は多くは非常に軽度で、ほとんどが目立たない白い線や筋ができる程度である。しかし、まれにフッ素症が顕著に現れることもあり、歯の見た目に悪影響を及ぼすこともある。 何を調べようとしたのか? フッ化物を添加した水道...

統合失調症がある人やその家族を対象とした介入は、標準治療よりも効果的なのか?

1 year ago
統合失調症がある人やその家族を対象とした介入は、標準治療よりも効果的なのか? 要点 - 家族介入によって統合失調症がある人の再発を減少させる可能性がある。 - 家族介入は介護者の負荷を軽減する可能性が高く、統合失調症がある人の家族における感情表出(家族関係や交流関係を含む患者にとって不利な家族環境)を改善する可能性がある。 - 統合失調症がある人とその家族に対する家族介入について確かな結論を出すためには、さらなる研究が必要である。 統合失調症とはどのような病気で、家族にどのような影響を及ぼすのか? 統合失調症は深刻で長期にわたる精神障害である。統合失調症がある人は、妄想、幻覚、まとまらない言動、活動性やセルフケアの低下、あるいはこれらの症状の組み合わせに悩まされることがある。また、回復してもまた病気になる(再発)ことが多い。治療は通常長期的で、薬物療法と、社会技能訓練、会話療法、行動療法などの「心理社会的」介入が含まれ、統合失調症がある人の症状の回復と管理を支援する。家族は病気の家族の世話において重要な役割を担っており、その結果、家族に精神的苦痛や大きな負担がかかり、統合失調症がある人の再発リスクを高める可能性がある。家族への介入は、家族の知識、感情、行動、そして家族環境全体を改善することに焦点を当て、それによって家族の幸福と患者の症状管理に利益をもたらす。プライバシーや家族への...

心理的または教育的な介入(もしくはその両方)は自宅で生活している高齢者の転倒を減らすことができるか?

1 year ago
心理的または教育的な介入(もしくはその両方)は自宅で生活している高齢者の転倒を減らすことができるか? 主なメッセージ - 心理的な介入、すなわち動機づけ面接(「変わりたい一方で変わりたくない」のような不確定な気持ちを丁寧に引き出し、個人の内発的動機づけを促すことで行動変容を目指す方法)とコーチングを含む介入に、それに合わせた教育的な介入(運動や薬物療法に関するアドバイスなど)を組み合わせても、転倒する人数(転倒者)はほとんど、あるいは全く変わらないが、転倒する回数は減少する可能性が高い(ただし、どの程度減少するかは不明)。 - 個々の心理的または教育的な介入の効果を確信できるほどの十分に質の高いエビデンスはなかった。 調べたかったこと 年齢を重ねるにつれ、転びやすくなり、ケガをする可能性が高くなる。高齢者の3人に1人が毎年転倒していると推定され、転倒は自立した生活や健康寿命に影響を及ぼす可能性がある。転倒はさまざまな理由で起こるが、それぞれの危険因子(筋力低下、視力、環境、薬など)に合わせた運動や介入を行うことで、転倒を減らすことができる。転倒するかもしれないと不安になれば、行動を制限することになり、転倒リスクが高まる可能性がある。心理的な介入は、転倒に対する不安を軽減し、転倒を予防するための行動をとる意識や意欲を高めることを目的としている。教育的な介入は、転倒のリスクを減らす方...

小児喘息の発作における非侵襲的陽圧換気法

1 year ago
小児喘息の発作における非侵襲的陽圧換気法 要点 ・どの研究でも、死亡または重篤な好ましくない事象は一切報告されていない(1件で挿管率(気管へのチューブ挿入)の報告があるのみ)。 ・非侵襲的陽圧換気は喘息症状スコアの改善、挿管率の低下につながり、小児集中治療室の滞在期間がわずかに短縮される可能性があるが、この結果の確実性は非常に低い。 小児喘息の発作に対してどのような治療が行われるか 喘息は世界的に重要な公衆衛生上の課題で、経済的な影響も大きい。喘息のある小児には、入院や、場合によって集中治療室入室が必要となる発作がしばしば起きる。 喘息発作に対する治療は、特に集中治療室に入室した小児の場合、主に、気道の筋肉を弛緩させる気管支拡張剤と炎症を抑えるステロイド(薬)の吸入または静脈内投与(静脈内への注入)である。これらの患者の多くは、うまく呼吸ができないので、持続陽圧換気(CPAP)や二相性陽圧換気(BiPAP)などの非侵襲的陽圧換気(NPPV)の形で呼吸補助が行われる。これらはいずれも侵襲的な人工気道を使わずに陽圧による呼吸補助を行う方法である。CPAPでは、かかる圧力は呼吸のサイクルを通じて一定だが、BiPAPでは息を吸うときには、吐くときよりも高い圧力がかかる。この陽圧はしばしば、フロージェネレーター(加圧空気供給装置)に接続された鼻マスクまたは(鼻と口を覆う)顔面マスクを介して...

Water fluoridation less effective now than in past

1 year ago

An updated Cochrane review has found that the dental health benefits of adding fluoride to drinking water may be smaller now than before fluoride toothpaste was widely available. 

The team of researchers from the Universities of Manchester, Dundee and Aberdeen reviewed the evidence from 157 studies which compared communities that had fluoride added to their water supplies with communities that had no additional fluoride in their water. They found that the benefit of fluoridation has declined since the 1970s, when fluoride toothpaste became more widely available. 

The contemporary studies were conducted in high-income countries. The impact of community water fluoridation in low- and middle-income countries is less clear, due to the absence of recent research.  

Fluoride, used in many commercially available toothpastes and varnishes, is known to reduce tooth decay. Governments in many countries have added fluoride to the drinking water supply to improve population oral health, although there are polarized views on whether this is the right action to take.  

“When interpreting the evidence, it is important to think about the wider context and how society and health have changed over time,” says co-author Anne-Marie Glenny, Professor of Health Sciences Research at the University of Manchester. “Most of the studies on water fluoridation are over 50 years old, before the availability of fluoride toothpaste. Contemporary studies give us a more relevant picture of what the benefits are now.”  

Results from studies conducted after 1975 suggest that the initiation of water fluoridation schemes may lead to slightly less tooth decay in children’s baby teeth. Analysis of these studies, covering a total of 2,908 children in the UK and Australia, estimates that fluoridation may lead to an average of 0.24 fewer decayed baby teeth per child. However, the estimate of effect comes with uncertainty, meaning it’s possible that the more recent schemes have no benefit. By comparison, an analysis of studies with 5,708 children conducted in 1975 or earlier estimated that fluoridation reduced the number of decayed baby teeth, on average by 2.1 per child.  

The same contemporary studies (conducted after 1975) also looked at the number of children with no decay in their baby teeth. The analysis found that fluoridation may increase the number of children with no tooth decay by 3 percentage points, again with the possibility of no benefit. 

The review was only able to draw conclusions about the impact on children’s teeth, with similar findings across both baby and permanent teeth. There were no studies with adults that met the review’s criteria.  

“The evidence suggests that water fluoridation may slightly reduce tooth decay in children,” says co-author Dr Lucy O’Malley, Senior Lecturer in Health Services Research at the University of Manchester. “Given that the benefit has reduced over time, before introducing a new fluoridation scheme, careful thought needs to be given to costs, acceptability, feasibility and ongoing monitoring.” 

Advocates have suggested that one of the key benefits of water fluoridation is that it reduces oral health inequalities. This updated review sought to examine this question and did not find enough evidence to support this claim, although this doesn’t necessarily mean there is no effect. 

The review’s findings accord with recent observational studies including the LOTUS study, which compared anonymised dental health records with water fluoridation status for 6.4 million adults and adolescents in England between 2010 and 2020. People in fluoridated areas needed slightly fewer invasive dental treatments with no significant impact on inequalities. 

“Contemporary evidence using different research methodologies suggest that the benefits of fluoridating water have declined in recent decades,” says Tanya Walsh, Professor of Healthcare Evaluation at the University of Manchester, co-author on both the Cochrane review and the LOTUS study. “Oral health inequalities are an urgent public health issue that demands action. Water fluoridation is only one option and not necessarily the most appropriate for all populations.” 

“Whilst water fluoridation can lead to small improvements in oral health, it does not address the underlying issues such as high sugar consumption and inadequate oral health behaviours,” says co-author Janet Clarkson, Professor of Clinical Effectiveness, University of Dundee. “It is likely that any oral health preventive programme needs to take a multi-faceted, multi-agency approach.” 

Iheozor-Ejiofor Z, Walsh T, Lewis SR, Riley P, Boyers D, Clarkson JE, Worthington HV, Glenny A-M, O'Malley L. Water fluoridation for the prevention of dental caries. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD010856. DOI: 10.1002/14651858.CD010856.pub3.

 

Friday, October 4, 2024
Mia Parkinson

認知症や軽度認知障害のある人にとって、エクサゲームの利益とリスクは何か?

1 year 1 month ago
認知症や軽度認知障害のある人にとって、エクサゲームの利益とリスクは何か? 要点 - 体を動かすビデオゲーム(「エクサゲーム」)は、認知症や軽度認知障害のある人の学習や項目の記憶といった思考能力の向上に役立つ可能性があるが、完全な確証はない。 - 現時点では、認知症や軽度認知障害のある人の歩行能力、バランス能力、支払いや買い物などの日常生活能力を向上させるのに役立つ可能性を示唆するエビデンスはほとんどない。 認知症と軽度認知障害とは? 認知症は、記憶力、思考力、日常業務遂行能力に影響を及ぼすような脳の変化を伴う疾患である。物事を記憶したり、計画を立てたり、集中したり、コミュニケーションをとったりすることが難しくなる。こうした変化は通常、時間とともに悪化し、最終的には日常生活に支障をきたすようになる。 軽度の認知障害とは、記憶や思考に何らかの問題があることを意味するが、認知症のある人ほど重度ではない。しかし、後に認知症になる可能性もある。軽度認知障害のある人は、物事を思い出したり、はっきりと考えたりすることに苦労することがあっても、請求書の支払いや買い物に行ったり、家をきれいに保ったりといった日常的な仕事はこなすことができる。基本的には、認知症ほど重度ではないが、時間の経過とともに進行する可能性のある、記憶や思考の困難があるようなものだ。 エクサゲーム(体性感覚ゲーム)とは何か? 現...

Cochrane welcomes global commitment to evidence synthesis

1 year 1 month ago

At the United Nations Summit of the Future, two major funding bodies announced £54.2 million of new funding for evidence synthesis: £45 million from Wellcome and £9.2 million from UK Research and Innovation (UKRI).

The announcements represent significant investment in evidence synthesis to help tackle global inequity and address the UN’s Sustainable Development Goals. Cochrane was represented at the summit by our Editor in Chief, Dr Karla Soares-Weiser.

“It is invigorating to see major global funders recognizing the importance of evidence synthesis in addressing the challenges facing the world today and in the future,” says Karla. “This significant investment has the potential to catalyze a step change in evidence synthesis, making it more timely, relevant and equitable. Cochrane has a proud history of advancing evidence synthesis, and we stand ready to support this vital global effort. I am especially excited at the potential to reduce global inequities in both producing and accessing high-quality evidence.”

Both funding calls are aimed at building infrastructure to support rapid evidence synthesis projects so that policymakers have access to the latest evidence on a given topic. The Wellcome announcement focuses on ‘living evidence synthesis’, where systematic reviews are continually updated so they always reflect the latest evidence. Wellcome’s announcement notes that ‘the Cochrane Collaboration, which produces gold-standard evidence syntheses in medicine, increasingly backs living evidence models’.

Living evidence

Cochrane is a pioneer of living systematic reviews, having published the world’s first living systematic reviews in 2017. Lessons from the pilot project were published in 2019, in a project co-led by Professor Tari Turner at Cochrane Australia, who serves on Cochrane’s Editorial Board and is Academic Director of the Australian Living Evidence Collaboration.

“It’s fantastic to see this global commitment to living evidence and recognition of Cochrane's leadership in this area,” says Tari. “The new funding is fantastic news for both evidence synthesis professionals and decision-makers who need up-to-date evidence. Living reviews come with many opportunities and challenges which we identified in our pilot programmes, and it’s great to see them getting the attention they deserve.”

 

Tuesday, September 24, 2024
Harry Dayantis

Cochrane’s pioneering role in living evidence

1 year 1 month ago

As the pace of new research accelerates, keeping systematic reviews up-to-date with the latest evidence has become increasingly vital. Cochrane is at the forefront of this evolution with our leadership in living systematic reviews (LSRs)—a dynamic approach that ensures evidence remains current and relevant.

What's a systematic review?
A systematic review attempts to identify, appraise, and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a specific research question. Researchers conducting systematic reviews use explicit, systematic methods that are selected with a view aimed at minimizing bias, to produce more reliable findings to inform decision making. 

For those new to the concept, here's a short video from Cochrane Consumers and Communication that explains what a systematic review is, how researchers prepare them, and why they’re a crucial part of making informed health decisions  - both for professionals and the public.

What is living evidence?
Living evidence refers to a systematic review that is continually updated to incorporate new and relevant information as it becomes available. Unlike traditional systematic reviews, which may be updated infrequently or not at all, living systematic reviews (LSRs) are underpinned by ongoing, active monitoring of the evidence base.

Key Features of LSRs:

  • Continual Monitoring: LSRs involve regular, often monthly, searches for new evidence.
  • Immediate Updates: New important evidence, including data, studies, or information, is promptly included.
  • Up-to-Date Communication: The status of the review and any new evidence are communicated clearly and regularly.

While LSRs employ the same core review methods as other Cochrane Reviews, they also incorporate predefined and transparent decisions on how frequently new evidence is sought, how it is integrated, and the rationale behind these decisions. Cochrane continues to innovate by providing updated information on the status of our reviews and each updated review is assigned a new citation and DOI, linking it to previous versions and ensuring the most current evidence is available.



Watch all the videos from this series

Why living systematic reviews?

LSRs represent a significant advancement in evidence synthesis, connecting evidence and practice more seamlessly than traditional methods. They are hugely valuable to healthcare professionals, decision-makers, guideline developers,  policy-makers, funders, consumers (patients and carers), and publishers who require up-to-date evidence for informed decision-making.

Technological advancements, such as online platforms, linked data, and machine learning, have made large-scale living evidence approaches feasible. The growth of collaborative research, open data initiatives, and citizen science also supports the maintenance of high-value datasets and LSRs - areas that Cochrane is also leading.

Cochrane’s role and innovations

Since launching the world's first pilot living reviews in 2017, Cochrane has been a trailblazer in this field. Professor Tari Turner, member of the Cochrane Library Editorial Board and Director of the Australian Living Evidence Collaboration based at  Cochrane Australia, has been instrumental in developing and applying living evidence approaches. According to Tari:

"Living evidence synthesis is transforming how we navigate uncertainty and make evidence accessible. By continually updating our living reviews, Cochrane is ensuring that decision-makers have the most current information at their fingertips."

Living systematic reviews are a testament to Cochrane's commitment to producing evidence that is not only trustworthy but also continuously relevant. As we move forward, we remain dedicated to leading in this space and advancing the field of evidence synthesis.

Monday, October 28, 2024
Muriah Umoquit

成人が足首(足関節)を骨折した後の回復に役立つのはどのようなアプローチか?

1 year 1 month ago
成人が足首(足関節)を骨折した後の回復に役立つのはどのようなアプローチか? 主なメッセージ - 手術後3週間以内に、骨折した足首に体重をかけると、回復が早まる可能性がある。しかし、早まる期間は短いかもしれない。 - 手術後6週間は、取り外しができる足首用サポーター(怪我をした足首を伸ばしたり動かしたりできる)を使用すると、回復が早まるかもしれない。しかし、繰り返しになるが、早まる期間は短いかもしれない。 - 足首を骨折した後の回復に向けた理学療法の価値を評価する十分なエビデンスはない。 足首の骨折 足首の骨折は、最も一般的な骨折のひとつである。骨折を治すために手術が必要なこともあれば、足首が治るまでの数週間、サポーターだけで対応できることもある。骨折が治るには通常6週間ほどかかるが、日常生活を今まで通りに送るためには、もっと長い時間がかかることもある。この回復の時期には、足首の動きや筋力、あるいはその両方を改善させるために、さまざまなアプローチを用いることができる。 回復のためにはどのようなアプローチがあるか? - 体重を早期にかける(早期荷重)か、遅れてかける(遅延荷重)か:手術後3週間以内に足首に体重をかけ始めるように勧められることもある。あるいは、最初の6週間ほどは、骨折した足首に一切体重をかけないように言われることもある。 - 取り外しができる足首用サポーター、または取り...

脳卒中後の成人の筋肉や腱の短縮による関節の拘縮の改善に対して支援技術は役立つか?

1 year 1 month ago
脳卒中後の成人の筋肉や腱の短縮による関節の拘縮の改善に対して支援技術は役立つか? 主なメッセージ ・質の低い研究が7件しか見つからなかったため、支援技術による治療が通常の治療より優れているかどうかについて確信をもって結論づけることはできない。 ・脳卒中後の成人の拘縮管理における支援技術の有益性と有害性を評価するためには、さらなる研究が必要である。 拘縮とは? 脳卒中後、多くの人は筋肉や腱が短くなったり硬くなったりすることで手足の変形を起こす。拘縮の主な原因は、手足が縮んだ状態で動かなくなることである。 支援技術とは? 支援技術とは、電気刺激や機械的な手段、例えばスプリント(プラスチック製の患部を固定する装具)などを使って筋肉や軟部組織を伸ばす装置のことである。 知りたかったこと 脳卒中後の成人の他動的な関節可動域(外部からの補助によって関節をどれだけ動かせるか)と拘縮部分の衛生状態を改善するために、どのような支援技術が、通常の治療、治療なし、あるいは別の支援技術よりも優れているかどうかを知りたかった。また、支援技術による有害事象があるかどうかも知りたかった。 実施したこと 支援技術の効果を、治療なし、通常の治療、または別の支援技術と比較して評価している研究を探した。研究結果を比較し、まとめた上で、研究方法や研究規模などの要素に基づくエビデンスの確実性を評価した。 わかったこと 支...